A new combination treatment shows early promise in GEP-NECs
Lurbinectedin and irinotecan demonstrate a synergic clinical effect in patients with neuroendocrine carcinomas of gastroenteropatic primary site after chemotherapy failure
Can sarcomas benefit from targeted treatments active in other tumour types?
Two studies in sarcoma explore the promise of ADCs and theranostics realised in different tumours.
New hope for MDM2 inhibition in liposarcomas?
An early-phase trial shows the efficacy of brigimadlin in dedifferentiated and well-differentiated liposarcomas, but confirmation from phase III results is still awaited
Desmoid tumours: nirogacestat improves quality of life also in stable disease
In a post hoc analysis of the DeFi trial, a reduction in symptom burden was reported, with benefits occurring early in treated patients
Studies provide further evidence to support continued imatinib in two different GIST indications
Uninterrupted imatinib is essential to optimise outcomes in metastatic and high-risk resected GIST
Most women report poor sexual health after a diagnosis of breast cancer
However, patients’ sexual concerns are often unaddressed in oncology, a study suggests
How to predict long-term survival to assess eligibility for phase I trials?
Studies investigate the discriminatory capacity of existing prognostic scales and the factors associated with survival to help select patients who may benefit from participation in early phase trials
Machine learning may help to uncover new immunotherapy targets
A study proposes a model that is able to learn broad aspects of cancer–immune interactions from early phase trial data
Novel antigens for cancer immunotherapy – a way to enhance effectiveness?
Research is ongoing to revisit the classic neoantigen approach that may better interpret the complexity of the immune system
Long-term data confirm a survival benefit with adjuvant anthracycline-taxane-based chemotherapy in early breast cancer
Updated analysis of the ABC trials favors anthracycline-based regimens in terms of IDFS and RFI, but no OS, when compared to taxane-based chemotherapy